IMT Header

Cambridge Healthtech Institute’s Second Annual
Rational Combination Cancer Immunotherapy
A forward looking view at the science and strategies that will inform development of the most effective immunotherapy combinations
August 25-26


The clinical and regulatory successes of the PD-1 and CTLA-4 checkpoint proteins are driving a resurgence of interest in immunotherapy as a mainstream form of cancer treatment, with numerous clinical studies exploring the application of these therapeutics in combinations with traditional and experimental agents.  CHI’s 2nd Annual Rational Combination Cancer Immunotherapy takes a forward-looking perspective on the design of drug products and treatment progressions that will build on the knowledge arising from these exploratory trials. The meeting will explore the scientific assumptions, patient diagnostic inputs and historical basis for different immunotherapy combinations – and consider new paradigms for the clinical studies that will evaluate these programs in the progression from research to commercialization. 

As a precursor to this ImVacS meeting, the Third Annual Immunomodulatory Therapeutic Antibodies for Cancer will examine the field from the perspective of mainstream and emerging targets, new indications and research challenges.

The organizers invite proposals for the conference that offer presentations of new data, new approaches and novel science from industry scientists or academic research groups working to research and develop highly effective immunotherapy combinations.

Topics may include, but are not limited to: 

Keynote Presentation: Lessons from Combining Ipilimumab and Nivolumab 

Biomarkers to Support Combination Immunotherapy  

  • Advances in biopsy and tissue analysis
  • Clinical trial design for validation of immunotherapy biomarkers
  • FDA perspective on development and application of immunotherapy biomarkers
  • Multivariate analyses of clinical and pathological factors
  • Profiling the antigen repertoire of a tumor microenvironment
  • Prognostic biomarkers in blood
  • TILs as potential immunotherapy biomarkers

Rational Combination Immunotherapy Strategies  

  • Combinations impacting the tumor microenvironment
  • Combinations targeting immune cells of different lineages
  • Combinations to reverse T cell dysfunction
  • Combinations with chemotherapy, radiation, tumor ablation
  • Combinations with targeted therapy 
  • Combinations with myeloid cells
  • Dose and sequence considerations in combination design
  • Effective cancer vaccines for use in combination immunotherapy
  • Lessons from recent combination trials – What may or may not work and why
  • Push/pull strategy: combining an inhibitor with an agonist

Modeling and Systems Biology in Designing Immunotherapy Combinations  

  • Applying systems biology to cancer immunotherapy
  • Big data role in identifying correlations between clinical response/benefit for immunotherapies
  • Collating data across current combination trials
  • Histological and molecular approaches to understanding the time course behavior of tumors
  • Mathematical modeling for early diagnosis and dormant metastasis
  • Preclinical models to predict behavior of combinations in the clinic
  • Rational combination design in early drug development

Clinical Study of Immunotherapy Combinations  

  • De-risking and trial design options for immunotherapy combinations
  • Mechanistic and post-market studies
  • New thinking on registration endpoints for cancer immunotherapies
  • Oncologist perspectives on immunotherapy combinations
  • Standardizing data protocols in immunotherapy trials

Scientists who wish to present their knowledge and expertise to their colleagues are asked to click here to submit an abstract.  Remember to specify the conference that you are interested in and please provide your full contact information.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality conference program.  

If you are interested in presenting, please submit a speaking proposal for review.  Replies to proposals can take up to 8-12 weeks. We will notify you once the agenda has been finalized.

Deadline for submission is February 2, 2015. 

We welcome your comments, suggestions and speaker suggestions as we shape the 2015 program

For more details on the conference, please contact:
Kent Simmons
Conference Director
Cambridge Healthtech Institute
T: (+1) 207-869-9199
E: ksimmons@healthtech.com 

For exhibit & sponsorship opportunities, please contact:
Katelin Fitzgerald
Sr. Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5458
E: kfitzgerald@healthtech.com